INVO - INVO BioScience GAAP EPS of -$0.90 misses by $0.05 revenue of $0.8M
2023-04-17 16:12:28 ET
- INVO BioScience press release ( NASDAQ: INVO ): FY GAAP EPS of -$0.90 misses by $0.05 .
- Revenue of $0.8M (-80.8% Y/Y).
- Selling, general and administrative expenses for the years ended December 31, 2022 and 2021 were $10.6 million and $9.0 million, respectively, of which $2.2 million and $2.7 million,
- Loss from equity investments for the years ended December 31, 2022 and 2021, were $0.2 million and $0.3 million, respectively.
- Adjusted EBITDA (see Adjusted EBITDA Table) for the year ended December 31, 2022, was $(8.4) million, which included $0.8 million loss attributable to our joint ventures, compared to adjusted EBITDA of $(2.8) million for the year ended December 31, 2021,
- As of December 31, 2022, the Company had approximately $0.1 million in cash.
For further details see:
INVO BioScience GAAP EPS of -$0.90 misses by $0.05, revenue of $0.8M